Emily Rose Derbyshire

Image of Emily Rose Derbyshire

Assistant Professor of Chemistry

The Derbyshire Lab uses both chemical tools and biological methods to uncover novel aspects of malaria parasite biology with the ultimate aim of identifying druggable targets. Projects range from developing assays for phenotypic and target-based screens to exploring biological pathways and identifying small molecules with potential therapeutic value. Their interdisciplinary collaborative program integrates chemical biology, molecular biology and biochemistry to globally interrogate parasite biology.

Appointments and Affiliations

  • Assistant Professor of Chemistry
  • Assistant Professor in Molecular Genetics and Microbiology

Contact Information:

  • Office Location: 3218 French Science Center, Durham, NC 27708
  • Office Phone: (919) 660-1511
  • Email Address: emily.derbyshire@duke.edu
  • Web Page:

Education:

  • Harvard Medical School, 2014
  • Ph.D. University of California at Berkeley, 2008
  • B.S. Trinity College, 2002

Courses Taught:

  • CHEM 393: Research Independent Study
  • CHEM 394: Research Independent Study
  • CHEM 493: Research Independent Study
  • CHEM 494: Research Independent Study
  • CHEM 517: Molecules in Life and Disease
  • MGM 293: Research Independent Study I
  • MGM 593: Research Independent Study

Representative Publications:

  • Totzke, J; Gurbani, D; Raphemot, R; Hughes, PF; Bodoor, K; Carlson, DA; Loiselle, DR; Bera, AK; Eibschutz, LS; Perkins, MM; Eubanks, AL; Campbell, PL; Fox, DA; Westover, KD; Haystead, TAJ; Derbyshire, ER, Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease., Cell chemical biology, vol 24 no. 8 (2017), pp. 1029-1039.e7 [10.1016/j.chembiol.2017.07.011] [abs].
  • Kato, N; Comer, E; Sakata-Kato, T; Sharma, A; Sharma, M; Maetani, M; Bastien, J; Brancucci, NM; Bittker, JA; Corey, V; Clarke, D; Derbyshire, ER; Dornan, GL; Duffy, S; Eckley, S; Itoe, MA; Koolen, KMJ; Lewis, TA; Lui, PS; Lukens, AK; Lund, E; March, S; Meibalan, E; Meier, BC; McPhail, JA; Mitasev, B; Moss, EL; Sayes, M; Van Gessel, Y; Wawer, MJ; Yoshinaga, T; Zeeman, A-M; Avery, VM; Bhatia, SN; Burke, JE; Catteruccia, F; Clardy, JC; Clemons, PA; Dechering, KJ; Duvall, JR; Foley, MA; Gusovsky, F et al., Diversity-oriented synthesis yields novel multistage antimalarial inhibitors., Nature, vol 538 no. 7625 (2016), pp. 344-349 [10.1038/nature19804] [abs].
  • Raphemot, R; Posfai, D; Derbyshire, ER, Current therapies and future possibilities for drug development against liver-stage malaria., Journal of Clinical Investigation, vol 126 no. 6 (2016), pp. 2013-2020 [10.1172/jci82981] [abs].
  • Raphemot, R; Lafuente-Monasterio, MJ; Gamo-Benito, FJ; Clardy, J; Derbyshire, ER, Discovery of Dual-Stage Malaria Inhibitors with New Targets., Antimicrobial agents and chemotherapy, vol 60 no. 3 (2015), pp. 1430-1437 [10.1128/aac.02110-15] [abs].
  • Herman, JD; Pepper, LR; Cortese, JF; Estiu, G; Galinsky, K; Zuzarte-Luis, V; Derbyshire, ER; Ribacke, U; Lukens, AK; Santos, SA; Patel, V; Clish, CB; Sullivan, WJ; Zhou, H; Bopp, SE; Schimmel, P; Lindquist, S; Clardy, J; Mota, MM; Keller, TL; Whitman, M; Wiest, O; Wirth, DF; Mazitschek, R, The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs., Science Translational Medicine, vol 7 no. 288 (2015) [10.1126/scitranslmed.aaa3575] [abs].